GlaxoSmithKline Pharmaceuticals Ltd (GSK) has reported revenue from operations for the quarter at Rs. 805 crores, profit before exceptional Items and tax at Rs. 228 crores with EBITDA margins at 27%.

In a flat General Medicines represented market during the quarter, GSK recorded 1% value growth despite the NLEM impact. Augmentin improved its market share and retained No. 1 rank in the IPM (Indian Pharmaceutical Market). Vaccines market and portfolio continued to deliver sequential growth. GSK will continue to invest in building newer capabilities to improve reach and access for its innovative portfolio comprising Shingrix, Nucala and Trelegy.

Commenting on the results, Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited said, "We remain committed to new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India. We will continue to drive operational efficiency and explore new innovative solutions including omnichannel strategy to expand reach and coverage to the target segments."